“ORAL COMMUNICATION | Semaglutide Plus Empagliflozin Improves Renal Outcomes Compared With Monotherapies in Type 2 Diabetes: A Real-World Study”. Italian Journal of Medicine 20, no. s1 (May 22, 2026). Accessed May 22, 2026. https://www.italjmed.org/ijm/article/view/2593.